Oncology 路 Cancer Research 路 Tumour Evolution 路 Precision Medicine
Pancreatic cancer remains one of the most challenging cancers to treat because tumour cells can adapt, spread, and become less responsive to available therapies. Scientists are investigating how changes in the genetic makeup of cancer cells help tumours evolve under treatment pressure鈥攁nd whether understanding these changes could lead to more effective therapies.
The central research question is important: Can scientists predict how pancreatic cancer will evolve before it becomes resistant to treatment?
This research could eventually help doctors identify treatment-resistant cancer cells earlier, select more appropriate therapies, and develop strategies that target the tumour’s ability to adapt. However, laboratory findings are an early step, not proof that a new treatment will work in patients.
What the latest research discovered
A study published in Nature Genetics on October 13, 2026, and highlighted in ScienceDaily on October 25, examined how pancreatic ductal adenocarcinoma (PDAC) evolves. Researchers analysed 443,451 individual cells from 62 tumours belonging to 56 patients. They found substantial genetic and biological diversity within individual tumours, helping explain why some cancer-cell populations may behave more aggressively than others.
One particularly promising finding involved the gene MYC. In laboratory experiments, inhibiting MYC activity caused aggressive cancer cells to shift towards a less aggressive cellular state. The cells also appeared more exposed to immune cells, raising the possibility that changing tumour behaviour could help the immune system recognise cancer more effectively.
These results are encouraging, but important limitations remain. The researchers have not demonstrated that blocking MYC cures pancreatic cancer in people, and the findings do not establish a new standard of treatment.
Introduction: Understanding One of the Most Challenging Cancers
Pancreatic cancer is among the most difficult cancers to treat. It can grow without producing obvious symptoms in its early stages, spread to nearby tissues, and develop resistance to treatments that initially slow its progression. Although surgery, chemotherapy, targeted medicines and selected immunotherapies can help some patients, the disease continues to present major challenges for modern oncology.
Scientists are increasingly investigating a fundamental question: why do some cancer cells survive treatment while others are destroyed?
Recent research highlighted by ScienceDaily on October 25, 2026, offers important insights into this question. Investigators associated with NYU Langone Health and its Perlmutter Cancer Center examined how pancreatic cancer cells change their genetic characteristics and biological behaviour as tumours develop. Their findings suggest that pancreatic cancer is not a uniform collection of identical cells. Instead, a tumour may contain multiple genetically distinct populations that behave differently and respond differently to treatment.
The study, published in Nature Genetics, analysed more than 443,000 individual cells from pancreatic tumours. The researchers identified diverse cancer-cell populations and investigated how genetic differences relate to tumour aggressiveness, cellular identity and interactions with the immune system.
One particularly interesting discovery involved MYC, a gene associated with cell growth and cancer progression. In laboratory experiments, blocking MYC activity shifted some aggressive pancreatic cancer cells towards a less aggressive state.
This discovery does not mean that a cure has been found. However, it provides a valuable direction for future research: instead of simply trying to destroy cancer cells, scientists may be able to interfere with the biological processes that allow tumours to evolve, spread and escape treatment.
What Is Pancreatic Cancer?
The pancreas is an organ located behind the stomach. It performs two major functions: producing digestive enzymes that help break down food and releasing hormones, including insulin, that regulate blood glucose.
Cancer can develop in different types of pancreatic cells. One of the most common and aggressive forms is pancreatic ductal adenocarcinoma, commonly abbreviated as PDAC. It develops from cells associated with the pancreatic ducts, which carry digestive fluids.
PDAC is particularly difficult to manage because it can invade surrounding tissues, spread to distant organs and develop complex interactions with its surrounding environment. Some patients are diagnosed only after the disease has advanced, when surgery may no longer be possible.
Treatment depends on the stage of cancer, the patient’s overall health, tumour characteristics and other clinical factors. Options can include surgery, chemotherapy, radiation therapy in selected situations, and targeted treatments for certain molecular changes.
Despite these advances, many patients experience recurrence or disease progression. Understanding the biological reasons behind these outcomes is therefore a major priority for cancer researchers.
The Latest Research: Examining Hundreds of Thousands of Individual Cells
Traditional cancer research often examines tumour samples as a whole. These methods can reveal important genetic mutations and patterns of gene activity, but they may overlook differences between individual cancer cells.
Imagine examining a forest only by measuring its average height and colour. Such measurements could miss the fact that some trees are young, others are diseased, and a small number are growing unusually quickly. A similar limitation can occur when scientists analyse an entire tumour without separating its different cellular populations.
The recent pancreatic cancer study addressed this challenge by examining individual cells.
Researchers analysed 443,451 cells from 62 tumours belonging to 56 patients with pancreatic ductal adenocarcinoma. They also used additional spatial gene-expression information from a subset of tumours to investigate how cancer cells and their surrounding environments were organised. Samples collected before and after chemotherapy from a small subset of patients offered further opportunities to study treatment-associated differences.
The research revealed substantial diversity within individual tumours. Different cancer-cell populations, known as clones, can possess distinct genetic characteristics and biological behaviours. Some may retain a more classical cellular identity, while others may display a basal-like identity associated with more aggressive disease.
The researchers found approximately two to eleven distinct clones in individual tumours, illustrating how complex a single cancer can be.
This diversity matters because a treatment that works against one population may not have the same effect on another. Understanding the composition of a tumour could therefore help scientists develop more precise strategies for controlling the disease.
How Tumours Evolve and Develop Treatment Resistance
Cancer evolution refers to changes in cancer-cell populations over time. These changes may arise through genetic alterations, differences in gene regulation and the selection of cells that survive particular conditions.
A tumour does not necessarily contain one fixed population of cancer cells. Instead, it can consist of several populations with different characteristics.
When treatment begins, susceptible cells may be destroyed or prevented from growing. However, some cells may possess characteristics that allow them to survive. These surviving populations can subsequently multiply, making the tumour increasingly difficult to control.
This process is often described as treatment selection. It does not mean that cancer cells consciously decide to resist medicine. Rather, biological variation and changes within the tumour can favour cells that tolerate treatment more effectively.
Resistance can develop through several mechanisms. Cancer cells may acquire genetic changes that reduce a drug’s effectiveness, activate alternative growth pathways, change their cellular identity or interact differently with surrounding tissues. In some cases, cells may also enter temporary biological states that make them less vulnerable to treatment.
The recent research adds to evidence that genetic diversity and changes in cellular identity are important parts of pancreatic cancer progression.
If scientists can identify the mechanisms that allow aggressive cell populations to emerge, they may eventually be able to design treatments that prevent or delay these changes.
MYC: A Potential Target for Changing Cancer Behaviour
One of the study’s most notable findings concerned MYC, a gene involved in regulating cell growth, metabolism and other important cellular processes.
MYC activity can become abnormally elevated in several types of cancer. When its regulation is disrupted, it can support processes that help cancer cells grow and maintain aggressive characteristics.
In the pancreatic cancer study, researchers observed elevated MYC activity in some of the more aggressive cancer-cell populations. They then investigated whether blocking MYC could influence these cells’ behaviour.
In laboratory experiments, inhibiting MYC activity shifted aggressive basal-like pancreatic cancer cells towards a more classical cellular state. The altered cells also appeared more exposed to immune cells.
This result is scientifically important because it suggests that the biological state of a cancer cell may be influenced by molecular processes that researchers could potentially target.
Rather than treating every aggressive cancer cell as biologically unchangeable, scientists can investigate whether certain features of its behaviour can be modified.
However, several questions remain unanswered. Researchers must establish whether the same changes can be produced consistently in living organisms, whether they can be achieved safely, and whether they meaningfully improve treatment outcomes.
MYC also performs important functions in normal cells, making selective and effective inhibition a significant therapeutic challenge.
The findings should therefore be considered a promising research direction rather than evidence of an available MYC-based cure for pancreatic cancer.
Why Cancer Cells Change Their Identity
Cancer cells can differ not only in their DNA but also in the genes they actively use.
Gene expression determines how genetic information is used to produce RNA and proteins. Changes in gene expression can influence a cell’s growth, metabolism, immune interactions and other biological properties.
In pancreatic cancer, researchers often distinguish between classical and basal-like cellular states. These categories describe patterns of gene activity and biological characteristics rather than two completely separate diseases.
Classical tumour cells generally display a different molecular programme from basal-like cells, which are frequently associated with more aggressive behaviour and poorer outcomes.
The recent study helped clarify how genetic differences within tumours relate to these cellular identities.
Understanding this relationship may eventually allow researchers to identify the molecular processes that encourage cancer cells to adopt more dangerous characteristics.
It is important to distinguish changes in gene activity from changes in DNA sequence. A cell can alter its behaviour because its genes are regulated differently, even when the underlying DNA sequence remains unchanged. Cancer evolution may involve both genetic alterations and changes in gene regulation.
This distinction matters for treatment development. Some mechanisms may require therapies that target specific genetic alterations, while others may be influenced by medicines that interfere with signalling pathways or cellular regulation.
How Pancreatic Cancer Interacts With the Immune System
The immune system can recognise and destroy abnormal cells, but cancer develops several ways to reduce the effectiveness of this defence.
Tumours can alter the signals they produce, influence immune cells in their surroundings and create an environment that makes immune attacks less effective.
Pancreatic cancer is particularly challenging because its surrounding tissue, often called the tumour microenvironment, contains a dense mixture of connective tissue, signalling molecules, blood vessels and different immune-cell populations.
These components can influence how cancer grows, how medicines reach tumour cells and how effectively immune cells recognise malignant tissue.
The recent study identified differences in the activity of immune-related genes among some pancreatic cancer-cell populations. Certain clones showed increased TIGIT-related activity alongside reduced PDCD1, the gene that encodes the PD-1 immune checkpoint protein.
These observations may help researchers understand why pancreatic cancer often responds poorly to some immune checkpoint therapies.
However, gene-expression findings alone do not establish exactly how a tumour behaves in every patient. The immune environment is complex, and individual tumours can differ substantially.
The researchers’ MYC experiments are particularly interesting because changing cancer-cell behaviour appeared to increase exposure to immune cells. Future studies will need to determine whether this translates into improved immune recognition and meaningful tumour control.
Could This Research Improve Immunotherapy?
Immunotherapy aims to help the immune system recognise and attack cancer. Some treatments block immune checkpoints, which are regulatory mechanisms that can limit immune responses.
PD-1 inhibitors have transformed treatment for several cancers, but they have shown limited benefit for most patients with pancreatic cancer when used without an appropriate indication or treatment combination.
One reason is that pancreatic tumours often have biological characteristics that make immune recognition difficult. The tumour microenvironment, genetic diversity and differences in immune signalling may all contribute.
The latest research raises the possibility that changing cancer-cell identity could influence how visible those cells are to immune defences.
If further studies confirm this effect, researchers might investigate whether therapies that alter tumour biology can be combined with immunotherapy in carefully selected circumstances.
Another potential direction is studying immune-related targets such as TIGIT. Scientists are investigating whether blocking particular immune-regulatory mechanisms can strengthen antitumour responses, although the effectiveness and safety of these approaches in pancreatic cancer remain to be established.
Importantly, the study does not demonstrate that inhibiting MYC or TIGIT will improve survival for patients with pancreatic cancer. It provides biological evidence that may help researchers formulate and test future treatment strategies.
Personalised Medicine: Why One Treatment May Not Work for Everyone
Personalised medicine aims to select treatments according to the characteristics of an individual’s disease.
In oncology, this can involve examining tumour DNA, identifying molecular alterations, measuring gene expression and assessing other biological features that may influence treatment response.
The latest pancreatic cancer research supports the idea that tumour biology is more complicated than a single genetic test may reveal.
Two patients can have cancers arising in the same organ but with different molecular characteristics. Even within one patient’s tumour, different cell populations may respond differently to treatment.
In the future, researchers may investigate whether detailed tumour profiling can identify populations that are more likely to resist a particular medicine.
For example, if a tumour contains a prominent population with a specific resistance-associated pathway, doctors might eventually have additional information to guide treatment selection or clinical-trial eligibility.
Researchers may also investigate whether repeat sampling or blood-based tests can detect changes in tumour biology over time.
These approaches remain under development. A laboratory discovery does not automatically become a clinically useful test, and any proposed test must demonstrate that it produces reliable information that improves patient care.
Nevertheless, a better understanding of tumour diversity could help move cancer treatment towards strategies that account for how a tumour changes rather than treating it as a static target.
Liquid Biopsies and Monitoring Cancer Evolution
A traditional tumour biopsy involves collecting tissue for laboratory examination. Although this provides valuable information, it can be difficult to obtain samples repeatedly, particularly when tumours are located in challenging anatomical positions.
Liquid biopsies offer another approach. They analyse biological material, such as circulating tumour DNA, that may be released into the bloodstream by cancer cells.
In some settings, circulating tumour DNA can help researchers detect particular genetic alterations, monitor changes associated with treatment and investigate the emergence of resistance.
However, liquid biopsies have limitations. Some tumours release very little detectable tumour DNA, and a negative result does not necessarily mean that cancer is absent. The usefulness of a test also depends on the cancer type, disease stage, assay design and clinical question.
For pancreatic cancer, future research could investigate whether repeated molecular measurements reveal changes in the tumour’s genetic composition before conventional assessments show progression.
Combining liquid biopsies with tissue analysis, imaging and clinical information may eventually provide a more complete picture of tumour evolution.
The new single-cell research does not itself establish a new blood test for detecting treatment resistance. Instead, it helps identify biological mechanisms that future monitoring approaches might investigate.
Challenges Before These Findings Can Benefit Patients
Despite the promise of the findings, translating laboratory discoveries into effective treatments takes time.
First, scientists need to validate the results in additional tumour samples and independent research studies. A biological pattern observed in one cohort may not occur equally across all patients.
Second, researchers must determine whether MYC inhibition can be achieved effectively in the human body. A laboratory experiment may use conditions that cannot be reproduced safely or consistently in patients.
Third, scientists must establish whether changing cancer-cell identity produces lasting benefits. A tumour may contain several resistant populations, and modifying one population might not eliminate other mechanisms of resistance.
Fourth, treatment safety is essential. MYC participates in normal cellular functions, so a therapy that affects this pathway must be evaluated carefully for unwanted effects on healthy tissues.
Fifth, clinical trials must determine whether a potential therapy improves meaningful outcomes, such as tumour control, quality of life or survival, compared with existing treatment approaches.
Finally, pancreatic cancer varies between patients. Future therapies may need to be selected according to molecular characteristics rather than offered identically to everyone.
These challenges do not diminish the value of the research. They explain why the journey from laboratory discovery to clinical treatment requires careful validation.
What Patients Should Know Today
The latest findings provide useful scientific insights, but they should not be interpreted as a recommendation to change current cancer treatment.
Patients with pancreatic cancer should discuss treatment options with their oncology team. Depending on the diagnosis, these may include surgery, chemotherapy, molecular testing, approved targeted medicines, selected immunotherapies or participation in a suitable clinical trial.
A clinician can determine whether additional molecular testing is appropriate and whether a particular clinical trial is suitable for the patient’s situation.
Experimental approaches targeting MYC or other mechanisms of tumour evolution should not be treated as proven therapies simply because laboratory experiments show promising results.
Patients and families should also be cautious about claims that a particular food, supplement or home remedy can reverse cancer-cell evolution. There is no established evidence that such approaches can replace evidence-based cancer treatment.
The most responsible interpretation is that scientists are learning more about how pancreatic cancer behaves and are using those discoveries to develop better research questions and potential therapeutic strategies.
The Future of Pancreatic Cancer Treatment
The study represents a broader shift in cancer research: understanding not only which mutations cause cancer, but also how cancer-cell populations change and interact over time.
Future research may combine single-cell sequencing, spatial biology, molecular profiling, advanced imaging and computational analysis to identify the processes that support tumour progression.
Researchers may also explore whether targeting more than one pathway can prevent cancer cells from switching to alternative survival mechanisms.
Another important direction is investigating combinations of treatments that target tumour growth while improving immune recognition. Such strategies will require careful laboratory testing and clinical trials to determine which combinations are effective and safe.
Artificial intelligence and advanced computational methods may eventually help researchers analyse large amounts of molecular data, identify patterns associated with treatment resistance and generate hypotheses for experimental testing. These methods will still require validation using reliable biological evidence and patient outcomes.
The goal is not merely to discover more genetic changes. It is to determine which changes are clinically important and whether targeting them helps patients live longer or experience a better quality of life.
Conclusion: Can Understanding Tumour Evolution Lead to Better Treatments?
Recent research into pancreatic cancer provides a clearer picture of how different cancer-cell populations can contribute to disease progression and treatment resistance.
By examining more than 443,000 individual cells, scientists identified extensive diversity within pancreatic tumours and investigated the relationship between genetic characteristics, cellular identity and aggressive behaviour.
The discovery involving MYC is particularly promising. In laboratory experiments, blocking its activity shifted some aggressive cancer cells towards a less aggressive state and made them appear more exposed to immune cells.
These findings suggest that tumour evolution may provide new opportunities for therapeutic intervention. Instead of focusing exclusively on destroying cancer cells, future strategies may also attempt to prevent them from adopting biological states that make them harder to treat.
However, further research is essential before these findings can guide routine clinical care. Scientists must establish whether the effects can be reproduced safely in patients and whether they improve treatment outcomes.
For now, the study offers an important advance in understanding pancreatic cancer biology. Its greatest potential lies in helping researchers develop more precise ways to anticipate resistance, target aggressive tumour populations and design treatments that account for the changing nature of cancer.
The future of pancreatic cancer research may depend not only on identifying what makes cancer grow, but also on understanding how it adapts鈥攁nd finding ways to interrupt that process.